From the Guidelines
Dosage Comparison
Trulicity (dulaglutide) pen is administered at a dose of 0.75 mg subcutaneously once weekly, which can be titrated to 1.5 mg once weekly for additional glycemic control 1, whereas semaglutide is administered at a dose of 0.25 mg subcutaneously once weekly, which can be increased to 0.5 mg and then to 1 mg once weekly for glycemic control 1.
- The recommended dosing for Trulicity is 0.75 mg or 1.5 mg subcutaneously once weekly 1.
- The recommended dosing for semaglutide is 0.25 mg, 0.5 mg, or 1 mg subcutaneously once weekly 1.
- It's worth noting that semaglutide also has an oral formulation, which is administered at a dose of 3 mg once daily, but this is not directly comparable to the subcutaneous formulation of Trulicity 1.
- The dosing regimens for both medications are designed to provide a sustained release of the active ingredient over a period of time, with Trulicity providing a 7-day release and semaglutide providing a weekly release 1.
- The 1 mg daily dose of semaglutide is not a standard dosing regimen for this medication, as it is typically administered once weekly for the treatment of type 2 diabetes 1.
From the Research
Dosage Comparison
- The dosage of Trulicity (dulaglutide) pen is 0.75 or 1.5 mg once weekly 2, 3, 4.
- The dosage of semaglutide is 1 mg daily 5, 6.
Key Differences
- Trulicity (dulaglutide) is administered once weekly, while semaglutide is administered once daily 5, 6.
- Trulicity (dulaglutide) has a higher dosage range (0.75 or 1.5 mg) compared to semaglutide (1 mg) 2, 3, 4.
Mechanism of Action
- Both Trulicity (dulaglutide) and semaglutide are glucagon-like peptide-1 (GLP-1) receptor agonists, which work by stimulating insulin secretion, suppressing glucagon secretion, and delaying gastric emptying 2, 5, 6, 4.
Efficacy and Safety
- Both Trulicity (dulaglutide) and semaglutide have been shown to be effective in improving glycemic control and reducing body weight in patients with type 2 diabetes 2, 5, 3, 6, 4.
- The safety profiles of both medications are similar, with gastrointestinal symptoms (such as nausea, vomiting, and diarrhea) being the most commonly reported adverse events 2, 5, 3, 6, 4.